Share on LinkedInShare on LinkedIn

ARTICLE · 13 AUGUST 2024

Patent Litigation Spotlight In Cancer Treatment

Patent litigation cases often read like a legal thriller, filled with twists, turns, and high-stakes drama. One recent case that exemplifies this narrative is the patent dispute between Natera and NeoGenomics.

United StatesIntellectual Property

By Babak Akhlaghi on August 9, 2024. Patent litigation cases often read like a legal thriller, filled with twists, turns, and high-stakes drama. One recent case that exemplifies this narrative is the patent dispute between Natera and NeoGenomics. This case, decided by the U.S. Court of Appeals for the Federal Circuit on July 12, 2024, offers a fascinating glimpse into the complex world of intellectual property rights and the fierce battles in patent litigation that can ensue over innovative technologies. Natera, Inc. v. NeoGenomics Laboratories, Inc. Case No. 24-1324 (Fed. Cir. July 12, 2024) (Moore, CJ; Taranto, Chen, JJ.)

The Players

Natera, Inc. and NeoGenomics are healthcare companies specializing in oncology testing. They both produce products for early cancer relapse detection. Natera holds two patents, U.S. Patent Nos. 11,519,035 and 11,530,454, issued in December 2022. The '035 patent covers methods for amplifying targeted genetic material, like cfDNA,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from